Sign up to save your podcasts
Or
Share A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.07.31.230870v1?rss=1
Authors: Blume, C., Jackson, C. L., Spalluto, C. M., Legebeke, J., Nazlamova, L. A., Conforti, F., Perotin-Collard, J.-M., Frank, M., Crispin, M., Coles, J., Thompson, J., Ridley, R. A., Dean, L. S., Loxham, M., Azim, A., Tariq, K., Johnston, D. A., Skipp, P. J., Djukanovic, R., Baralle, D., McCormick, C. J., Davies, D. E., Lucas, J. S., Wheway, G., Mennella, V.
Abstract:
Angiotensin-converting enzyme 2 (ACE2) is the main entry point in the airways for SARS-CoV-2. ACE2 binding to SARS-CoV-2 protein Spike triggers viral fusion with the cell membrane, resulting in viral RNA genome delivery into the host. Despite ACE2's critical role in SARS-CoV-2 infection, an understanding of ACE2 expression, including in response to viral infection, remains unclear. Until now ACE2 was thought to encode five transcripts and one 805 amino acid protein. Here we identify a novel short isoform of ACE2. Short ACE2 is expressed in the airway epithelium, the main site of SARS-CoV-2 infection; it is substantially upregulated in response to interferon stimulation and RV infection, but not in response to SARS-CoV-2 infection, and it shows differential regulation in asthma patients. This short isoform lacks SARS-CoV-2 spike glycoprotein high-affinity binding sites and altogether our data are consistent with a model where short ACE2 may influence host susceptibility to SARS-CoV-2 infection.
Copy rights belong to original authors. Visit the link for more info
View all episodes
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.07.31.230870v1?rss=1
Authors: Blume, C., Jackson, C. L., Spalluto, C. M., Legebeke, J., Nazlamova, L. A., Conforti, F., Perotin-Collard, J.-M., Frank, M., Crispin, M., Coles, J., Thompson, J., Ridley, R. A., Dean, L. S., Loxham, M., Azim, A., Tariq, K., Johnston, D. A., Skipp, P. J., Djukanovic, R., Baralle, D., McCormick, C. J., Davies, D. E., Lucas, J. S., Wheway, G., Mennella, V.
Abstract:
Angiotensin-converting enzyme 2 (ACE2) is the main entry point in the airways for SARS-CoV-2. ACE2 binding to SARS-CoV-2 protein Spike triggers viral fusion with the cell membrane, resulting in viral RNA genome delivery into the host. Despite ACE2's critical role in SARS-CoV-2 infection, an understanding of ACE2 expression, including in response to viral infection, remains unclear. Until now ACE2 was thought to encode five transcripts and one 805 amino acid protein. Here we identify a novel short isoform of ACE2. Short ACE2 is expressed in the airway epithelium, the main site of SARS-CoV-2 infection; it is substantially upregulated in response to interferon stimulation and RV infection, but not in response to SARS-CoV-2 infection, and it shows differential regulation in asthma patients. This short isoform lacks SARS-CoV-2 spike glycoprotein high-affinity binding sites and altogether our data are consistent with a model where short ACE2 may influence host susceptibility to SARS-CoV-2 infection.
Copy rights belong to original authors. Visit the link for more info